Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial - Senzer,N.; Arsenau,J.; Richards,D.; Berman,B.; MacDonald,J.R.; Smith,S. (Am J Clin Oncol, 2005)